

Generic Name: Vismodegib

Therapeutic Class or Brand Name: Erivedge

Applicable Drugs (if Therapeutic Class): N/A

Preferred: N/A

Non-preferred: N/A

Date of Origin: 2/1/2013

Date Last Reviewed / Revised: 2/13/2023

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through IV are met)

- I. Documented diagnosis of one of the following conditions A through B AND must meet criteria listed under applicable diagnosis:
 - A. Metastatic Basal Cell Carcinoma
 - B. Locally Advanced Basal Cell Carcinoma and one of the criteria 1 or 2 is met:
 1. The patient is not a candidate for surgery or radiation therapy.
 2. Carcinoma has recurred following surgery.
- II. Minimum age requirement: 18 years old.
- III. Treatment is prescribed by or in consultation with an oncologist.
- IV. Request is for a medication with the appropriate FDA labeling, or its use is supported by current clinical practice guidelines.

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

- 30 capsules per 30 days

APPROVAL LENGTH

- **Authorization:** 1 year
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

N/A

REFERENCES

1. Erivedge. Prescribing information. Genentech USA; July 2020. Accessed February 13, 2023. http://www.gene.com/download/pdf/erivedge_prescribing.pdf.
2. NCCN Clinical Practice Guidelines in Oncology. Basal Cell Skin Cancer. V.2.2022. Updated March 24, 2022. http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed February 13, 2023.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.